Interim condensed consolidated statement of changes in shareholders' equity - EUR (€) |
Share capital |
Premiums related to share capital |
Net profit (loss) |
Translation Reserves |
Reserves (Accumulated losses) |
Total |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Balance at the beginning at Dec. 31, 2024 | € 957,000 | € 249,160,000 | € (184,212,000) | € 600,000 | € (173,151,000) | € (106,647,000) | |||||||||
| Balance at the beginning (in shares) at Dec. 31, 2024 | 95,662,391 | ||||||||||||||
| Net loss for the period | (175,882,000) | (175,882,000) | |||||||||||||
| Remeasurement of defined benefit plans | 93,000 | 93,000 | |||||||||||||
| Currency translation differences | (260,000) | (260,000) | |||||||||||||
| Total comprehensive loss | (175,882,000) | (260,000) | 93,000 | (176,049,000) | |||||||||||
| Appropriation of net income (loss) | 184,212,000 | (184,212,000) | |||||||||||||
| Issue of ordinary shares | [1] | € 435,000 | 135,115,000 | 135,550,000 | |||||||||||
| Issue of ordinary shares (in shares) | [1] | 43,488,883 | |||||||||||||
| Transaction costs | (7,519,000) | (7,519,000) | |||||||||||||
| Issue of prefunded warrants | [2] | 138,130,000 | 138,130,000 | ||||||||||||
| Share-based payment compensation expenses | 8,009,000 | 8,009,000 | |||||||||||||
| Treasury shares | 85,000 | 85,000 | |||||||||||||
| Other | (467,000) | (467,000) | |||||||||||||
| Balance at the end (in shares) at Jun. 30, 2025 | 139,151,274 | ||||||||||||||
| Balance at the end at Jun. 30, 2025 | € 1,392,000 | 376,755,000 | (175,882,000) | 340,000 | (211,513,000) | (8,909,000) | |||||||||
| Balance at the beginning at Dec. 31, 2024 | € 957,000 | 249,160,000 | (184,212,000) | 600,000 | (173,151,000) | € (106,647,000) | |||||||||
| Balance at the beginning (in shares) at Dec. 31, 2024 | 95,662,391 | ||||||||||||||
| Balance at the end (in shares) at Dec. 31, 2025 | 193,236,978 | 193,236,978 | |||||||||||||
| Balance at the end at Dec. 31, 2025 | € 1,932,370 | 528,230,262 | [3] | (354,138,000) | 636,000 | (205,182,000) | € (28,522,000) | ||||||||
| Net loss for the period | (69,467,000) | (69,467,000) | |||||||||||||
| Remeasurement of defined benefit plans | 73,000 | 73,000 | |||||||||||||
| Currency translation differences | (175,000) | (175,000) | |||||||||||||
| Total comprehensive loss | (69,467,000) | (175,000) | 73,000 | (69,570,000) | |||||||||||
| Appropriation of net income (loss) | 354,138,000 | (354,138,000) | |||||||||||||
| Issue of ordinary shares | [4] | € 430,000 | 123,899,000 | [3] | (21,132,000) | 103,197,000 | |||||||||
| Issue of ordinary shares (in shares) | [4] | 43,043,224 | |||||||||||||
| Transaction costs | (8,205,000) | [3] | (8,205,000) | ||||||||||||
| Issue of prefunded warrants | 49,933,000 | 49,933,000 | |||||||||||||
| Vesting of bonus shares | € 157,000 | 21,100,000 | |||||||||||||
| Share-based payment compensation expenses | 11,753,000 | 11,753,000 | |||||||||||||
| Treasury shares | 299,000 | 299,000 | |||||||||||||
| Other | 116,000 | € 116,000 | |||||||||||||
| Balance at the end (in shares) at Jun. 30, 2026 | 236,280,202 | 236,280,202 | |||||||||||||
| Balance at the end at Jun. 30, 2026 | € 2,362,802 | € 643,924,498 | [3] | € (69,467,000) | € 460,000 | € (518,278,000) | € 59,002,000 | ||||||||
| |||||||||||||||